JP2022541520A5 - - Google Patents

Info

Publication number
JP2022541520A5
JP2022541520A5 JP2022502928A JP2022502928A JP2022541520A5 JP 2022541520 A5 JP2022541520 A5 JP 2022541520A5 JP 2022502928 A JP2022502928 A JP 2022502928A JP 2022502928 A JP2022502928 A JP 2022502928A JP 2022541520 A5 JP2022541520 A5 JP 2022541520A5
Authority
JP
Japan
Prior art keywords
amino acid
composition according
acid sequence
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022502928A
Other languages
English (en)
Japanese (ja)
Other versions
JP7681277B2 (ja
JP2022541520A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/056635 external-priority patent/WO2021009684A1/en
Publication of JP2022541520A publication Critical patent/JP2022541520A/ja
Publication of JP2022541520A5 publication Critical patent/JP2022541520A5/ja
Application granted granted Critical
Publication of JP7681277B2 publication Critical patent/JP7681277B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022502928A 2019-07-15 2020-07-15 関節炎疾患の治療のための修飾aavキャプシドタンパク質 Active JP7681277B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2023505 2019-07-15
NL2023505 2019-07-15
PCT/IB2020/056635 WO2021009684A1 (en) 2019-07-15 2020-07-15 Modified aav capsid proteins for treatment of arthritic disease

Publications (3)

Publication Number Publication Date
JP2022541520A JP2022541520A (ja) 2022-09-26
JP2022541520A5 true JP2022541520A5 (enExample) 2023-07-21
JP7681277B2 JP7681277B2 (ja) 2025-05-22

Family

ID=68425203

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502928A Active JP7681277B2 (ja) 2019-07-15 2020-07-15 関節炎疾患の治療のための修飾aavキャプシドタンパク質

Country Status (23)

Country Link
US (1) US20220267797A1 (enExample)
EP (1) EP3999119B1 (enExample)
JP (1) JP7681277B2 (enExample)
KR (1) KR20220081971A (enExample)
CN (1) CN114502737B (enExample)
AU (1) AU2020314883A1 (enExample)
BR (1) BR112022000724A2 (enExample)
CA (1) CA3146791A1 (enExample)
DK (1) DK3999119T3 (enExample)
ES (1) ES2998884T3 (enExample)
FI (1) FI3999119T3 (enExample)
HR (1) HRP20241647T1 (enExample)
HU (1) HUE069369T2 (enExample)
IL (1) IL289826A (enExample)
LT (1) LT3999119T (enExample)
MX (1) MX2022000551A (enExample)
PH (1) PH12022550109A1 (enExample)
PL (1) PL3999119T3 (enExample)
PT (1) PT3999119T (enExample)
RS (1) RS66255B1 (enExample)
SI (1) SI3999119T1 (enExample)
SM (1) SMT202400486T1 (enExample)
WO (1) WO2021009684A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64499B1 (sr) * 2018-01-17 2023-09-29 Meiragtx Uk Ii Ltd Modifikovani protein kapsida raav za gensku terapiju
EP4413147A4 (en) 2021-10-08 2025-07-30 Dyno Therapeutics Inc CAPSID VARIANTS AND METHODS OF USE THEREOF
CN116444626A (zh) * 2021-12-28 2023-07-18 成都弘基生物科技有限公司 经过修饰的aav衣壳蛋白及其用途
WO2024191778A1 (en) 2023-03-10 2024-09-19 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2024213660A1 (en) 2023-04-13 2024-10-17 Meiragtx Uk Ii Limited Inflammation-inducible promoters
AU2024332181A1 (en) 2023-08-31 2026-02-12 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
TW202545971A (zh) 2024-02-08 2025-12-01 美商戴諾治療公司 殼體多肽及其使用方法
WO2026064442A2 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002360355B2 (en) 2001-11-09 2005-07-07 Government Of The United States Of America, Department Of Health And Human Services Production of adeno-associated virus in insect cells
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
EP3085389A1 (en) * 2005-04-07 2016-10-26 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
AU2006304997B2 (en) 2005-10-20 2012-03-01 Uniqure Ip B.V. Improved AAV vectors produced in insect cells
ES2785223T3 (es) 2006-06-21 2020-10-06 Uniqure Ip Bv Células de insecto para la producción de vectores de AAV
EP2061891B1 (en) 2006-08-24 2012-04-11 Virovek, Inc. Expression in insect cells of genes with overlapping open reading frames, methods and compositions therefor
EP2012122A1 (en) * 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
SI2173888T1 (sl) 2007-07-26 2017-01-31 Uniqure Ip B.V. Bakulovirusni vektorji, ki vsebujejo ponavljajoča kodirna zaporedja z različnimi kodonskimi preferencami
ES2644880T3 (es) 2008-02-19 2017-11-30 Uniqure Ip B.V. Optimización de expresión de proteínas Rep y Cap parvovirales en las células de insecto
EP2297185A1 (en) 2008-06-17 2011-03-23 Amsterdam Molecular Therapeutics (AMT) B.V. Parvoviral capsid with incorporated gly-ala repeat region
EP2545165B1 (en) 2010-03-11 2020-07-29 uniQure IP B.V. Mutated rep encoding sequences for use in aav production
AU2012304993B2 (en) 2011-09-08 2017-09-14 Uniqure Ip B.V. Removal of contaminating viruses from AAV preparations
WO2013174760A1 (en) * 2012-05-25 2013-11-28 Deutsches Krebsforschungszentrum Optimized aav-vectors for high transduction rates in dendritic cells
GB201403684D0 (en) * 2014-03-03 2014-04-16 King S College London Vector
EP3137497B2 (en) * 2014-05-02 2025-03-05 Genzyme Corporation Aav vectors for retinal and cns gene therapy
WO2016055437A1 (en) 2014-10-06 2016-04-14 Arthrogen B.V. Aav-based gene therapy
WO2017197355A2 (en) * 2016-05-13 2017-11-16 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and methods of use thereof
US11207382B2 (en) * 2016-08-19 2021-12-28 University Of Florida Research Foundation, Incorporated Compositions for treating conditions using recombinant self-complementary adeno-associated virus
KR20250121159A (ko) * 2016-12-07 2025-08-11 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 인터류킨-1 수용체 길항제(IL-1RA) cDNA
WO2018189244A1 (en) * 2017-04-11 2018-10-18 Ruprecht-Karls-Universität Heidelberg Adeno-associated virus library
RS64499B1 (sr) * 2018-01-17 2023-09-29 Meiragtx Uk Ii Ltd Modifikovani protein kapsida raav za gensku terapiju

Similar Documents

Publication Publication Date Title
KR102923245B1 (ko) Tslp-관련 질환에 대한 치료제의 개발 및 적용
IL275838B2 (en) A modified raav capsid protein for gene therapy
HRP20241647T1 (hr) Modificirani proteini aav kapsida za liječenje artritične bolesti
JP2021510528A5 (enExample)
EP0617126B1 (en) Polypeptide capable of inhibiting the binding between human IL-6 and its receptor
KR101522954B1 (ko) 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도
CN115043938B (zh) SARS-CoV-2及其突变株的抗体及应用
CN107787329B (zh) 以高亲和力、亲和性及特异性结合转化生长因子-β1的经修饰的IgG抗体
JP5512824B2 (ja) B型肝炎ウイルス表面抗原に特異的に結合するヒト抗体
CN105669863B (zh) 一种能与人内皮素受体特异性结合的抗体及其应用
HUT69995A (en) Monoclonal antibodies against the human interferon receptor, with neutralizing activity against type i interferon, compositions containing them and process for preparing them
TWI832847B (zh) Gipr抗體及其與glp-1的融合蛋白質,以及其藥物組合物和應用
WO1984002129A1 (fr) Proteine de l'interferon immun humain et son procede de preparation
KR20210084473A (ko) 항인간 Fn14 항체
WO2024125667A1 (zh) 一种针对SARS-CoV或SARS-CoV-2的单克隆抗体、其制备方法及应用
TW202216747A (zh) 包含類升糖素胜肽—1及介白素—1受體拮抗物的融合蛋白及其用途
JP7300008B2 (ja) 低免疫原性かつ低ADCC/CDC機能の抗TNF-αヒト化モノクローナル抗体TCX060およびその使用
KR100492820B1 (ko) 돼지 유행성 설사병 바이러스 중화 에피토프 및 이의 이용
WO2020233571A1 (zh) 一种双特异性分子及其制备与用途
WO2021143733A1 (zh) 一种融合蛋白及其制法和用途
WO2020248967A1 (zh) Eta抗体与bnp的融合蛋白质,以及其药物组合物和应用
WO2026017191A2 (zh) 抗il-5抗体、其药物组合物及用途
WO2026067440A1 (zh) Tslp/il-13双特异性抗体及其用途
HK40050252B (zh) 抗人fn14抗体
TW202613177A (zh) Gipr抗體及其與glp-1的融合蛋白質,以及其藥物組合物和應用